Free Newsletter
Merck chalks up another Vioxx victory
A Florida jury ruled for Merck in yet another Vioxx case, bringing the drug maker's record to 11-5 in trials related to the drug. The newest case involved a former professional soccer player, Refik Kozic, who had a heart attack in 2001 at the age of 50. The jury decided that Vioxx didn't cause Kozic's heart attack.
Merck, of course, pulled Vioxx from the market in 2004 because of increased risk of heart attack and stroke. Some 45,000 product liability cases are pending.
- check out Merck's release
Related Articles:
NY double-teams Merck in Vioxx lawsuit. Report
Merck takes tough stance on Vioxx. Report
Vioxx defense dealt a blow by new study results. Report
Up to 100,000 Vioxx claims expected. Report
Merck faces long road in Vioxx battle. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: